Amanda Adler MD, PhD, FRCP herself attended the Cambridge Diabetes Seminar. She trained in economics, medicine, and epidemiology, plus further training in pharmacoepidemiology and pharmacovigilance. She is Professor of Diabetic Medicine and Health Policy at the University of Oxford, where she directs the Diabetes Trails Unit, the unit responsible for the UK Prospective Diabetes Study (UKPDS), and collaborates with the Health Economics Research Centre.

She is a physician at Cambridge University Hospital Foundation Trust (Addenbrooke’s) and Royal Papworth Hospital. At the National Institute for Health and Care Excellence (NICE), she chaired an independent Technology Appraisal Committee for 12 years leading decisions for more than 130 drugs and devices across all disease areas. She also chaired: the NICE/NHS England/NHS Improvement Committee to develop innovative subscription pricing models for antimicrobials; the In vitro Advisory Group related monoclonal antibody treatments for COVID-19; a clinical guideline for type 2 diabetes; and, the Quality Standard for Diabetes. She works with NICE International including meeting with the Government of Ukraine in 2023. In 2019, she received an award for Distinguished Contribution to NICE at the Parliamentary ceremony celebrating NICE’s 20th anniversary.

She supports projects that set priorities under universal health coverage working with the International Decision Support Initiative (iDSI), the World Bank, and the Organisation for Economic Co-operation and Development (OECD). She is a Commissioner on the UK Commission on Human Medicines (CHM) and chairs its Cardiovascular, Diabetes, Renal, Respiratory and Allergy Expert Advisory Group. Until earlier this year, she chaired the World Health Organisation’s TAG (technical advisory group) for diabetes, and continues to co-chair the guideline group for insulin use in humanitarian and low resource settings.